-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Gw9/2hTnD7B7XDtydP5SHjFvirbY+ZtSzd2o4UJALSF1ogIG4fLdTUqDufU2wDz8 mQA6fqJ0c6IJjWEac3QuDg== 9999999997-08-047019.txt : 20081205 9999999997-08-047019.hdr.sgml : 20081205 20081205100928 ACCESSION NUMBER: 9999999997-08-047019 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20081205 DATE AS OF CHANGE: 20081205 20081205 20081205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 081231350 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C8@,"!O8FH@/#PO3&EN96%R:7IE9"`Q+TP@.#`Q M-B]/(#@O12`S.#4W+TX@,2]4(#-094P`3$+`P<#8Q(8AQ0S,#@P\#-YN"Q.?33-6U6`[`(4!U? M&52?!1"S,C#("D/$&3X!!!@`%\L'*`T*96YD7!E+U!A9V4^/@UE;F1O8FH-.2`P(&]B:CP\+T9O;G0\/"]45#(@,3`@,"!2 M+U14-"`Q,B`P(%(^/B]07!E+T9O;G0^/@UE M;F1O8FH-,3$@,"!O8FH\/"],96YG=&@@,3,X,2]&:6QT97(O1FQA=&5$96-O M9&4^/G-TW6TH/#6C#^GH79HRH)#N M1Y2!CW_XQ7CLT1@B/_;B$-+#R(>GD>M[OH]/TWQD1R^C;^3K>I4N'#?T8C*' MC>-R;T)2Q_<8F:;F\6(#SM_I'R-WXD4QN-2C'-*YB>=/;#PU4O$VB]G7AU6Z M8[WJIC\`888A(]_N9W<^9V;^:+W#/]!.D#XMI M^ADG'82X=<*OBV26"75H^G$!%D-$;]%A!M-9"O=+H$F@.&(D!)L+NPAX7?#$ M"X(W#LR'U''I]/!:R!*^/&?U([/<+^>U"LPP/&E9-;E<98!GJ-[DFT'"7_F[V1CU=-##U`&(;<1]=-#TX ML#APZF*XV240,F\UI:];(MA4[R$K(CD>T4D0*W-#*JH13N4-_/9P* M`2S?Q:H]IHZOSRE%-I#13N1-E*S-'J;^`MM8/1=8>G$3+3?4L M/,(LKAR*_VN0Y<7$/WB,_-C$;A9WZ_$`T?"KC4#"' M@ZAS-:QJ!$OCBR!-+O#M!%-FI5ZI3U=83HC*P3)M!*TX6]9"["KSFQ)HAZN) MV^.*#=R60;L0T[P=`X>OWL:;><`Y>R3;1^>1A(_.6$>>RQ_2=&2,;?O#60NR MEIA5];&J3="E5(D+>,;B=Z(5M1)`3&2)]'29Z6`W?1>1*ZM6">]XVJ)OBU?8 MR28OJD:@K#VC!.I[\>2L!=&AZW>2F.9Y5>_0N,7K&'J!=Q1&V#@R>\=P>M[R MXB%2]Q:ARU'.0,CP:E>`[*NBJ%Y45Q#&*%U)+/""Z*:FSAXOLBA`E;9%0<7J M#M'7>RT*D34.)Y@>%JWEAK]VU>-1AMU6FO/MMJ.H9;6#YBAR);*=WO5^D.35 M78F/R*V'T&2J01L/@74].,I,!#%F6OKX]L'"D!/46BN+[E?E;..%K:.,AR+L MMK%Q-V(^Y3H`.-3'.?3979L;AAR'\=EMX9L+C/\'WUT+4$U(XS5#CVF>9:/D M.5;>MUKN]&HEG=#K*\_P9B[OMU0]1G;JYJ2Z/E)F7KYTG,M&.UPGOK[D_(A)I?>$3?$G& M=Q89?=+Q\U%]J?>8RLQ?[/QV:S_H*;09;&P&1Q.DWYO;@;PY_RR:WC/3 M!]LT3NJ+D]+,&K4VN4X*TU2[P\@GEY+_']AUB;^ELT4Z^E>``0"(=`7!E+T9O;G0^/@UE M;F1O8FH-,3,@,"!O8FH\/"]3=&5M5B`Q,S8O1F]N=$YA;64O5&EM97-.97=2 M;VUA;E!3+4)O;&1-5"]&;VYT4W1R971C:"].;W)M86PO1F]N=%=E:6=H="`W M,#`O1FQA9W,@,S0O1&5S8V5N="`M,C$V+T9O;G1"0F]X6RTU-3@@+3,P-R`R M,#`P(#$P,C9=+T%S8V5N="`X.3$O1F]N=$9A;6EL>2A4:6UE'1' M4W1A=&4O4T$@9F%LFMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB,RXQ+3&UL;G,Z>&%P/2)H='1P.B\O;G,N861O M8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.D-R96%T;W)4;V]L/@H@ M("`@("`@("`\>&%P.DUO9&EF>41A=&4^,C`P."TQ,BTP-50Q,#HP-3HR-BTP M-3HP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@("`@(#QX87`Z0W)E871E1&%T M93XR,#`X+3$R+3`U5#$P.C`U.C(V+3`U.C`P/"]X87`Z0W)E871E1&%T93X* M("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I M;VX@&UL.FQA;F<](G@M9&5F875L="(^36EC&%P34TZ26YS=&%N8V5)1#YU M=6ED.CED.64T-S=F+3!B-C@M-#%D-2UA,V5F+6%E,F9F,&8Y-C0Y,#PO>&%P M34TZ26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO M6QI;B!0:&%R;6%C975T:6-A;',@26YC+BYD;V,I M/CX-96YD;V)J#7AR968-"C`@-@T*,#`P,#`P,#`P,"`V-34S-2!F#0HP,#`P M,#`S.#4W(#`P,#`P(&X-"C`P,#`P,#,X.3`@,#`P,#`@;@T*,#`P,#`P,SDQ M,R`P,#`P,"!N#0HP,#`P,#`S.38S(#`P,#`P(&X-"C`P,#`P,# -----END PRIVACY-ENHANCED MESSAGE-----